Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1546-170X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial ; volume:28 ; number:10 ; day:10 ; month:10 ; year:2022 ; pages:2083-2091 ; date:10.2022
Nature medicine ; 28, Heft 10 (10.10.2022), 2083-2091, 10.2022
- Urheber
-
Garvey, W. Timothy
Batterham, Rachel L.
Bhatta, Meena
Buscemi, Silvio
Christensen, Louise N.
Frias, Juan P.
Jódar, Esteban
Kandler, Kristian
Rigas, Georgia
Wadden, Thomas A.
Wharton, Sean
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-022-02026-4
- URN
-
urn:nbn:de:101:1-2022122921205400056834
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 07:20 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Garvey, W. Timothy
- Batterham, Rachel L.
- Bhatta, Meena
- Buscemi, Silvio
- Christensen, Louise N.
- Frias, Juan P.
- Jódar, Esteban
- Kandler, Kristian
- Rigas, Georgia
- Wadden, Thomas A.
- Wharton, Sean
- SpringerLink (Online service)
Ähnliche Objekte (12)
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Health economic aspects of overweight and obesity
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Health economic aspects of overweight and obesity
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction
Effect of semaglutide on cardiac structure and function in patients with obesity-related heart failure
Semaglutide in Obesity: Unmet Needs in Men
Semaglutide
Semaglutide treatment of hypothalamic obesity – a real-life data study
Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Semaglutide in HFpEF across obesity class and by body weight reduction: a prespecified analysis of the STEP-HFpEF trial
Health economic aspects of overweight and obesity
Semaglutide Treatment in a Patient with Extreme Obesity and Massive Lymphedema: A Case Report
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial
Semaglutide in patients with obesity and heart failure across mildly reduced or preserved ejection fraction